A Phase 3 interventional study of MK0928, gaboxadol / Duration of Treatment: 10 months in Insomnia, sponsored by H. Lundbeck A/S. Withdrawn. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-01-14.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
A study to evaluate the safety and effectiveness of an investigational drug for insomnia (a sleep disorder).
1,856 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 594 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →H. Lundbeck A/S is the lead sponsor of 218 studies on the registry; 10 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
4-hour advanced polysomnographic (PSG) recording session measuring wake time after sleep onset (WASO) and latency to persistent sleep (LPS); Safety and tolerability
Daily sleep diary for visual analogue sleep quality and number of night awakenings (sNAW)
No study locations are listed for this record.
This study is withdrawn, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sleep Initiation and Maintenance Disorders→
H. Lundbeck A/S